Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000985372 | SCV001133493 | uncertain significance | not provided | 2019-05-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001215723 | SCV001387483 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2019-07-01 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals with BRCA1-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces glycine with alanine at codon 57 of the BRCA1 protein (p.Gly57Ala). The glycine residue is highly conserved and there is a small physicochemical difference between glycine and alanine. |
Ambry Genetics | RCV002400157 | SCV002713516 | likely benign | Hereditary cancer-predisposing syndrome | 2021-07-02 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Brotman Baty Institute, |
RCV001076703 | SCV001242502 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro |